Although slowly expanding #lesions represent a small fraction of overall T2 lesions, they are highly prevalent across #MultipleSclerosis subtypes and partially overlap with paramagnetic rim lesions.
@neurologyadvisor.bsky.social
@neurologyadvisor.bsky.socialAlthough slowly expanding #lesions represent a small fraction of overall T2 lesions, they are highly prevalent across #MultipleSclerosis subtypes and partially overlap with paramagnetic rim lesions.
@newsramp.comQuantum BioPharma (QNTM) signs a Study Start-Up Agreement with Thermo Fisher Scientific to launch a Phase 2 trial of Lucid-MS, its first-in-class neuroprotective treatment for progressive multiple sclerosis, following FDA clearance. #MultipleSclerosis #ClinicalTrials
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) signs Study Start-Up Agreement with Thermo Fisher Scientific to advance its Phase 2 trial of Lucid-MS, a first-in-class neuroprotective treatment for progressive multiple sclerosis. #MultipleSclerosis #Biopharma
@modernbuddhism.bsky.social#meditation #modernbuddhismpodcast #peaceofmind #buddhism #meditate #ms #multiplesclerosis #multiplesclerosisawareness
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS into Phase 2 trials for multiple sclerosis while its unbuzzd spinout delivers a 7% royalty stream up to $250M. A dual-track strategy targeting both pharma and wellness markets. #Biotech #MultipleSclerosis
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS into a Phase 2 MS trial while holding a 20% stake and 7% royalty stream in alcohol-metabolism product unbuzzd. A dual pipeline worth watching. #Biotech #MultipleSclerosis
@msnewstoday.bsky.socialExplore the details: https://bit.ly/4elSxHq
A trial will test whether noninvasive nerve stimulation paired with hand rehab can improve function and support myelin repair in MS.
@kevjbyrne.bsky.socialIt’s a fight for my life, but not everything has to be serious. Dude, he’s back! #NeverStopNeverQuitForThem #MultipleSclerosis #MS #nationalmssociety #CanYouTRK
@morethanms.bsky.socialI knew I was safe inside the MRI. My body disagreed.
I got through it. The anxiety didn’t end there.
Two new essays: A Sliver of Outside and Fear of the Final Fall.
Both live: miguelallamani.com/notes
@abudd.bsky.social@abudd.bsky.social@abudd.bsky.social@abudd.bsky.social
@gregoryai.bsky.socialTolerogenic dendritic cell (tolDC) vaccines are a promising antigen-specific therapy for multiple sclerosis (MS), yet their efficacy is limited by poor homing to secondary lymphoid organs and rapid loss of the tolerogenic phenotype in na...
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #MedSky
@lightningduck.bsky.socialHad to collapse into bed after two hard MS days. Slept longer than expected but fell asleep feeling punched
Woke up and couldn't make dinner from the pain in my joints, fog in my thought and no gyros. Cooked microwave plate that I couldn't even eat
...
@morethanms.bsky.socialI thought getting through the MRI would be the whole story.
Nope.
The fear didn’t end when they pulled me out.
I ended up writing two connected essays about the experience. Both go up tomorrow in Notes from a Changed Life.
@kevjbyrne.bsky.socialLooking for some normal after Garage Dayz October! #NeverStopNeverQuitForThem #MultipleSclerosis #MS #nationalmssociety #CanYouTRK
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) receives FDA clearance for its Lucid-MS IND application, paving the way for a Phase 2 trial targeting myelin degradation in multiple sclerosis patients. A major milestone for this micro-cap biotech. #Biotech #MultipleSclerosis
@sroman.bsky.social@msnewstoday.bsky.socialGet the scoop: https://bit.ly/4yJn4qY
Scientists have engineered a human "mini-brain" model that mimics MS damage and repair, offering a new way to test myelin-repairing therapies.